Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...